PMID: 9557634Apr 29, 1998Paper

Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients

Journal of Virology
D DuraliE Gomard

Abstract

The great variability of protein sequences from human immunodeficiency virus (HIV) type 1 (HIV-1) isolates represents a major obstacle to the development of an effective vaccine against this virus. The surface protein (Env), which is the predominant target of neutralizing antibodies, is particularly variable. Here we examine the impact of variability among different HIV-1 subtypes (clades) on cytotoxic T-lymphocyte (CTL) activities, the other major component of the antiviral immune response. CTLs are produced not only against Env but also against other structural proteins, as well as some regulatory proteins. The genetic subtypes of HIV-1 were determined for Env and Gag from several patients infected either in France or in Africa. The cross-reactivities of the CTLs were tested with target cells expressing selected proteins from HIV-1 isolates of clade A or B or from HIV type 2 isolates. All African patients were infected with viruses belonging to clade A for Env and for Gag, except for one patient who was infected with a clade A Env-clade G Gag recombinant virus. All patients infected in France were infected with clade B viruses. The CTL responses obtained from all the African and all the French individuals tested showed freque...Continue Reading

References

Nov 11, 1990·Proceedings of the National Academy of Sciences of the United States of America·C F ScottJ E Robinson
Sep 1, 1990·AIDS·D F NixonA J McMichael
Mar 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·T J PalkerB F Haynes
Jan 1, 1989·AIDS·D P Bolognesi
Aug 1, 1995·Current Opinion in Immunology·J T Safrit, R A Koup
Jan 1, 1995·Nature Medicine·S Rowland-JonesT Corrah
Mar 9, 1995·Nature·D L RobertsonB H Hahn
Oct 1, 1993·AIDS Research and Human Retroviruses·E MurphyF Barré-Sinoussi
Feb 18, 1997·Proceedings of the National Academy of Sciences of the United States of America·G FerrariK J Weinhold

❮ Previous
Next ❯

Citations

Jan 15, 2003·Annual Review of Medicine·Mary Carrington, Stephen J O'Brien
Apr 18, 2003·AIDS·Mary Carrington, Ronald E Bontrop
Jun 28, 2003·Journal of Virology·Tracey J HarveyAlexander A Khromykh
Oct 22, 2003·Der Internist·J Wild, R Wagner
Jan 21, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Kenji SomeyaMitsuo Honda
Nov 21, 2001·British Medical Bulletin·B KorberV Detours
Aug 17, 2004·AIDS Research and Human Retroviruses·Alleluiah RutebemberwaFrances Gotch
Mar 18, 2003·AIDS Research and Human Retroviruses·Carolyn WilliamsonRonald Swanstrom
Feb 3, 2009·AIDS Research and Human Retroviruses·Nattawan Promadej-LanierJanet M McNicholl
Dec 19, 2002·AIDS Research and Human Retroviruses·Madhuri R ThakarRobert C Bollinger
Jun 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·A Ross LopesMala K Maini
Apr 3, 1999·Viral Immunology·L Menéndez-AriasE Domingo
Jan 28, 2006·AIDS Research and Human Retroviruses·Kelly R Young, Ted M Ross
Oct 27, 2005·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Lyle R McKinnonFrancis A Plummer
Dec 17, 2004·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Vanessa François-BongarconJudy Lieberman
Aug 3, 2005·AIDS Research and Human Retroviruses·André InwoleyUNKNOWN ANRS 1220 PRIMO-CI Study Group
Sep 25, 2002·Clinics in Laboratory Medicine·James P McGettiganMatthias J Schnell

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.